Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Regulatory Tracker: Brazil, China (Vol. 3 No. 45)

This article was originally published in PharmAsia News

Executive Summary

The Emerging Markets Regulatory Tracker is a periodic PharmAsia News feature that summarizes and links to important regulatory developments impacting the biopharma and medical device industries in the Asia Pacific region and other emerging markets.

You may also be interested in...



Emerging Markets Regulatory Tracker: India Plans Regulatory Overhaul

India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.

Emerging Markets Regulatory Tracker: China Self-Audit Results Released

China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.

Emerging Markets Regulatory Tracker: China Device Classifications

China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC084862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel